TriangleHEALTH PROFESSIONAL · SOURCE READING
Dasatinib
Source: Acute Lymphoblastic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 17, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment of Recurrent ALL / Treatment Options for Recurrent ALL
Patients with Ph-positive ALL are often taking imatinib at the time of relapse and thus have imatinib-resistant disease. Dasatinib is a novel tyrosine kinase inhibitor with efficacy against several different imatinib-resistant BCR::ABL1 fusion gene variants. Dasatinib has been approved for use in patients with Ph-positive ALL who are resistant to, or intolerant of, imatinib. The approval was based on a series of trials involving patients with chronic myeloid leukemia, one of which included small numbers of patients with lymphoid blast crisis or Ph-positive ALL.
Evidence (dasatinib):
In one study, ten patients were treated with dose-escalated dasatinib.[12] Seven of these patients had a complete hematologic response (<5% marrow blasts with normal peripheral blood cell counts), three of whom had a complete cytogenetic response.
Source links and citations
In one study, ten patients were treated with dose-escalated dasatinib.[12] Seven of these patients had a complete hematologic response (<5% marrow blasts with normal peripheral blood cell counts), three of whom had a complete cytogenetic response.
The common toxicities were reversible myelosuppression (89%) and pleural effusions (21%).
In one study, ten patients were treated with dose-escalated dasatinib.[12] Seven of these patients had a complete hematologic response (<5% marrow blasts with normal peripheral blood cell counts), three of whom had a complete cytogenetic response.
Virtually all of these patients relapsed within 6 months of the start of treatment with dasatinib.
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice